Drug-Induced Hepatotoxicity

1. Front Matter

   Pages I-XXXI

   PDF

2. Orientation in Liver Toxicity by Drugs

   • E. Farber

   Pages 1-23

3. Clinical Studies and Role of Necrosis in Hepatotoxicity

   • R. G. Cameron, L. M. Blendis

   Pages 25-42

4. Subcellular Biochemical and Pathological Correlates in Experimental Models of Hepatotoxicity

   • G. Feuee, F. A. Iglesia

   Pages 43-73

5. Molecular Biology of Hepatic Drug Reactions

   • R. W. Sallie, E. A. Jones

   Pages 75-97

6. In Vitro Models of Liver Toxicity

   • R. G. Thurman, P. E. Ganey, S. A. Belinsky, J. G. Conway, M. Z. Badr

   Pages 99-117

7. Cytochromes P450 and Liver Injury

   • J. S. Leeder, A. B. Okey

   Pages 119-153

8. Mechanisms of Drug-Induced Cholestasis

   • J. B. Watkins III, C. D. Klaassen

   Pages 155-171

9. Fatty Liver and Drugs

   • M. U. Dianzani

   Pages 185-210

10. Choline Deficiency: An Important Model for the Study of Hepatotoxicity

    • A. K. Ghoshal

    Pages 211-220

11. Immune Mechanisms and Liver Toxicity

    • I. R. MacKay

    Pages 221-247

12. Hepatic Encephalopathy

    • A. S. Basile

    Pages 249-271

13. Liver Drug Reactions and Pregnancy

    • F. Trevisani, D. H. van Thiel

    Pages 273-292

14. Pediatric Hepatic Drug Reactions

    • E. A. Roberts

    Pages 293-322

15. Reye’s Syndrome

    • R. R. Varma

    Pages 323-340

16. Drug Hepatotoxicity in the Elderly

    • K. Kitani

    Pages 341-366

17. Effect of Liver Disease on Drug Metabolism and Pharmacokinetics

    • P. G. Welling, W. F. Pool

    Pages 367-394

18. Liver Reactions to Tacrine

    • T. F. Woolf, W. P. Pool, R. M. Walker, D. K. Monteith

    Pages 395-410

19. Mechanisms of Hypertransaminemia

    • M. Pirmohamed, B. K. Park

    Pages 411-440

20. Diagnostic Tools and Clinical Pathology

    • D. C. Snover

    Pages 441-455

The advances in science and medicine we are now experiencing are unprec­ edented and exciting. Life expectancy is prolonged, and quality of life is much improved. We learn of fabulous new discoveries made at the bench or the bedside every week. Many diseases have been totally eliminated, others can be significantly improved by new therapeutic formulations. Much of the success can be attributed to a better understanding of disease processes and the specific targeting of new and more effective medications. As is the case in many areas of successful human endeavour, there can be a downside. In the case of drugs and chemicals it is their adverse effects which are of concern. Of course, every effort is made to devise medications that are safe, and the need to elucidate and understand mechanisms are crucial, yet adverse effects remain a problem. They can be unpredictable and diverse. Drugs have been shown to induce virtually the whole gamut of human liver pathology from acute fulminant hepatitis to chronic active hepatitis to cirrho­ sis and even malignancy. Hence the possibility of adverse drug effects must be considered in the differential diagnosis of many patients with liver disease. This is well recognized and is very important; indeed, removal of the offending agent can often lead to reversal of the adverse effect. This is an area of hepatology where we can really make a difference.

• Hepatotoxizität
• Leber
• Reye's syndrome
• drug
• hepatoxicity
• liver
• toxicity
• hepatology
• metabolic disease

• Department of Pathology Division of Experimental Pathology, University of Toronto, Toronto, Canada

  Ross G. Cameron

• Department of Clinical Biochemistry Banting Institute, University of Toronto, Toronto, Canada

  George Feuer

• Parke-Davis Pharmaceutical Research Division Department of Pathology and Experimental Toxicology, Warner Lambert Company, Ann Arbor, USA

  Felix A. Iglesia

Policies and ethics